18.94

1.35% -0.26

After Hours: 18.99 0.05 +0.26%

Summit Therapeutics Inc (SMMT)

Overview News Price History Option Chain Financials Why SMMT Down? Discussions Forecast

Summit Therapeutics Inc stock is traded at $18.94, with a volume of 1.35M. It is down -1.35% in the last 24 hours and down -10.91% over the past month. Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Previous Close:

$19.20

Open:

$19.49

24h Volume:

1.35M

Relative Volume:

0.27

Market Cap:

$14.09B

Revenue:

$956.00K

Net Income/Loss:

$-196.68M

P/E Ratio:

-11.27

EPS:

-1.6811

Net Cash Flow:

$-113.02M

1W Performance:

+1.72%

1M Performance:

-10.91%

6M Performance:

+460.36%

1Y Performance:

+842.29%

1-Day Range:

$18.76

$19.52

1-Week Range:

$18.03

$19.54

52-Week Range:

$1.89

$33.89

Summit Therapeutics Inc Stock (SMMT) Company Profile

Name

Summit Therapeutics Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

305-203-2034

Address

601 BRICKELL KEY DRIVE, MIAMI

Employee

105

Twitter

@summitplc

Next Earnings Date

2024-10-30

Latest SEC Filings

SMMT's Discussions on Twitter

Compare SMMT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SMMT Summit Therapeutics Inc	18.94	14.09B	956.00K	-196.68M	-113.02M	-1.6811
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-04-24	Initiated	JMP Securities	Mkt Outperform
Sep-27-24	Downgrade	Citigroup	Buy → Neutral
Aug-12-24	Initiated	H.C. Wainwright	Buy
May-07-24	Initiated	Citigroup	Buy
Mar-26-24	Initiated	Stifel	Buy
Jun-28-18	Downgrade	Janney	Buy → Neutral
May-02-18	Initiated	Janney	Buy
Apr-12-18	Reiterated	Needham	Buy
Feb-13-18	Initiated	BTIG Research	Buy
Jan-04-18	Initiated	SunTrust	Buy
Dec-01-17	Resumed	H.C. Wainwright	Buy
Nov-16-16	Reiterated	RBC Capital Mkts	Outperform
Oct-05-16	Reiterated	Needham	Buy
Sep-16-16	Initiated	H.C. Wainwright	Buy
Mar-30-15	Initiated	Needham	Buy
Mar-30-15	Initiated	Oppenheimer	Outperform

View All

Summit Therapeutics Inc Stock (SMMT) Latest News

Nov 26, 2024

Summit Therapeutics to Present at Upcoming Investor Conferences - BioSpace

Nov 26, 2024

Nov 23, 2024

3 Monster Stocks in the Making - The Motley Fool

Nov 23, 2024

Nov 21, 2024

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Nov 21, 2024

Nov 20, 2024

Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer? - MSN

Nov 20, 2024

Summit Therapeutics (SMMT) Hurt Bronte Capital. Here’s Why - Insider Monkey

Nov 20, 2024

Nov 18, 2024

Summit Therapeutics (NASDAQ:SMMT) Earns "Buy" Rating from HC Wainwright - MarketBeat

Nov 18, 2024

Nov 17, 2024

(SMMT) Trading Report - Stock Traders Daily

Nov 17, 2024

Nov 14, 2024

Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics - Investor's Business Daily

Nov 14, 2024

Merck signs up to $3.3 billion cancer drug deal with China-based LaNova - Reuters

Nov 14, 2024

Nov 13, 2024

BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential - Benzinga

Nov 09, 2024

Is Summit Therapeutics a Millionaire Maker? - AOL

Nov 09, 2024

Nov 08, 2024

Summit Therapeutics (NASDAQ:SMMT) Has Debt But No Earnings; Should You Worry? - Simply Wall St

Nov 08, 2024

Why Summit Therapeutics Stock Was a Winner Today - MSN

Nov 08, 2024

Nov 06, 2024

Trading (SMMT) With Integrated Risk Controls - Stock Traders Daily

Nov 06, 2024

Nov 04, 2024

SMMT Surges as Analyst Initiates Coverage with Buy Rating - GuruFocus.com

Nov 04, 2024

Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo - Yahoo Finance UK

Nov 04, 2024

Summit Therapeutics Leads the Parade of Big Gainers - GuruFocus.com

Nov 04, 2024

Summit Therapeutics shares rated Market Outperform by JMP Securities - Investing.com UK

Nov 04, 2024

Summit Therapeutics Leads The Parade Of Big Gainers - Forbes

Nov 04, 2024

Summit Therapeutics (NASDAQ:SMMT) Earns Market Outperform Rating from Analysts at JMP Securities - MarketBeat

Nov 04, 2024

This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy? - MSN

Nov 04, 2024

Nov 01, 2024

abrdn plc Invests $24.89 Million in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat

Nov 01, 2024

Oct 31, 2024

H.C. Wainwright cuts Summit Therapeutics stock target, maintains Buy amid study expansion - Investing.com Canada

Oct 31, 2024